

# “Why I reach for proplete®”

IDPN PROTEIN THERAPY

Proplete® is compounded according to physician prescription

patent pending

## Patient Satisfaction

“Proplete® was a lifesaver until my appetite returned. I hate to think what I would have weighed without it. I am now cancer-free. Proplete® was definitely a key part of my recovery.”

Rick Banks, age 44

ESRD and Multiple Myeloma, stem cell transplant 10/15/09  
Dayton Regional Dialysis, Huber Heights, Ohio

## Better Serum Albumin Levels

In a retrospective study conducted by Pentec Health (n=175), patients receiving Proplete® experienced a greater increase in mean serum albumin after 3 months of therapy than patients receiving traditional IDPN formulas.

PROPELITE® vs. TRADITIONAL IDPN FORMULATION*			
	PRE-ALBUMIN	3 MO. MEAN ALBUMIN	MEAN INCREASE ALBUMIN
PROPELITE®	2.86 ± .47	3.18 ± .40	.32 ± .53
TRADITIONAL IDPN	2.95 ± .51	3.22 ± .54	.26 ± .40
PATIENTS WITH DIABETES			
PROPELITE®	2.86 ± .49	3.18 ± .33	.31 ± .48
TRADITIONAL IDPN	2.93 ± .47	3.10 ± .52	.18 ± .37

A sub-population analysis showed that patients with diabetes receiving Proplete® experienced almost twice the increase in mean serum albumin after 3 months of therapy in comparison to patients with diabetes receiving traditional IDPN.

**The perfect balance of meeting patient protein needs and simplifying clinical management**

**Find out more: 866-956-IDPN(4376) or visit [pentechealth.com](http://pentechealth.com)**

\*Graph represents a retrospective analysis of Pentec Health's internal data base. Patients included in the analysis had a baseline albumin of <3.5mg/dL and received the same IDPN formula (traditional or Proplete®) for a minimum of 3 consecutive months. Patient groups included 83 patients who received traditional IDPN formulas containing higher dextrose and lipid and 92 patients who received Proplete®. The analysis compares baseline and 3 month serum albumin levels in each of these groups and a further sub-population analysis comparing patients with Diabetes in both groups: 41 patients receiving traditional IDPN formulas; 63 patients receiving Proplete®. Results were not statistically significant in either the traditional vs Proplete® formula analysis, (p= 0.127) nor the analysis of patients with Diabetes on either formula (p=0.59). The study was not powered to show any differences among various sub-populations within the study cohort.

PROPELITE is a registered trademark of Pentec Health, Inc.

Available exclusively from **pentec health**

4 Creek Parkway, Suite A

Boothwyn, PA 19061

[pentechealth.com](http://pentechealth.com)

